Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Viola Zilber

Physician Assistant, Medical Brooklyn, NY Physician Assistant

NPI 1881826162 CMS profile 10949807

3049 Brighton 6Th Street, Unit Cu1, Brooklyn, NY 11235

Open in the dashboard

General payments

$3,172

163 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Viola Zilber of Brooklyn, NY is reported in the CMS Open Payments database as having received $3,172 across 163 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $710 31
2024 General $926 40
2023 General $403 29
2022 General $602 33
2021 General $532 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Viola Zilber
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Viola Zilber were reported at $710. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Viola Zilber Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $532 $156 $41–$563 $132
2022 $602 $185 $55–$649 $149
2023 $403 $199 $58–$717 $160
2024 $926 $206 $62–$740 $164
2025 $710 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $1,056 51 payments
  2. AstraZeneca Pharmaceuticals LP $612 31 payments
  3. Arcutis Biotherapeutics, Inc. $165 9 payments
  4. Regeneron Healthcare Solutions, Inc. $160 7 payments
  5. Nestle HealthCare Nutrition Inc. $155 17 payments
  6. Pfizer Inc. $98 5 payments
  7. Amarin Pharma Inc. $91 4 payments
  8. ARS Pharmaceuticals Operations, Inc. $88 4 payments
  9. Novartis Pharmaceuticals Corporation $76 3 payments
  10. kaleo, Inc. $73 4 payments
  11. Other $599 28 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,172 163 payments
Products named General payments · program years 2021–2025
  1. NUCALA $563 26 payments
  2. TRELEGY ELLIPTA $361 19 payments
  3. BREZTRI $342 18 payments
  4. AIRSUPRA $211 9 payments
  5. SHINGRIX $188 8 payments
  6. ZENPEP $182 18 payments
  7. Zoryve $165 9 payments
  8. BOOSTRIX $103 5 payments
  9. EUCRISA $98 5 payments
  10. Vascepa $91 4 payments
  11. Other $1,311 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 101 drugs

Part D claims

3,696

Median for Physician Assistant: 241

Drug cost

$936,746

Median for Physician Assistant: $4,110

Branded share of claims

44.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zenpep Lipase/Protease/Amylase Brand 112 $223,465
Linzess Linaclotide Brand 148 $79,539
Eucrisa Crisaborole Brand 76 $55,286
Vascepa Icosapent Ethyl Brand 139 $46,905
Creon Lipase/Protease/Amylase Brand 33 $46,873
Diclofenac Potassium Generic 33 $44,177
Restasis Cyclosporine Brand 60 $39,261
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 62 $36,816
Breo Ellipta Fluticasone/Vilanterol Brand 91 $36,784
Ubrelvy Ubrogepant Brand 23 $32,063

The 10 drugs with the highest cost, of 101 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$8,807

Medicare's payments for the services billed

Medicare patients

53

Average age 78

Services billed

208

38 women, 15 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 64%
Depression 55%
Ischemic heart disease 51%
Heart failure 34%
Osteoporosis 32%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $189
$189 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $179
$179 62 —
Zoryve
  • Arcutis Biotherapeutics, Inc. $165
$165 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $159
$159 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $80
$80 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

163 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record